Metagenomi to Present at Upcoming Investor Conferences - Mar 24, 2022

EMERYVILLE, Calif.--(BUSINESS WIRE)-- Metagenomi, a genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced that it will present at two upcoming investor conferences.

  • H.C. Wainwright Gene Therapy and Gene Editing Conference
    Virtual
    Date: Wednesday, March 30, 2022
    Time: A pre-recorded presentation will be available on-demand, starting at 7:00 a.m. ET
    Participant: Simon Harnest, Chief Investment Officer and SVP, Strategy, Metagenomi
  • Goldman Sachs’ The New Guard: Privates Leading the Disruption in Healthcare
    In-person
    Date: Thursday, April 7, 2022
    Time: 10:00 a.m. ET
    Panel Title: Gene Editing: Moving from Molecular Scissors to Pencils
    Participants: Brian Thomas, PhD, CEO and Founder, Metagenomi; Simon Harnest, Chief Investment Officer and SVP, Strategy, Metagenomi

About Metagenomi

Metagenomi is a gene editing company committed to developing potentially curative therapeutics by leveraging a proprietary toolbox of next-generation gene editing systems to accurately edit DNA where current technologies cannot. Our metagenomics-powered discovery platform and analytical expertise reveal novel cellular machinery sourced from otherwise unknown organisms. We adapt and forge these naturally evolved systems into powerful gene editing systems that are ultra-small, extremely efficient, highly specific and have a decreased risk of immune response. These systems fuel our pipeline of novel medicines and can be leveraged by partners. Our goal is to revolutionize gene editing for the benefit of patients around the world. For more information, please visit https://metagenomi.co/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005862/en/

Contacts

Metagenomi

Investor:
Simon Harnest
CIO, SVP Strategy
simon@metagenomi.co
(917) 403-1051

Media:
Ashlye Hodge
Sr. Marketing and Communications Specialist
ashlye@metagenomi.co
(510) 734-4409

Source: Metagenomi

Back to news